source
- FDA sets May 1 decision date for uniQure's Huntington's disease gene therapy after year-long regulatory sagaThe U.S. Food and Drug Administration has accepted uniQure's biologics license application for its Huntington's disease gene therapy and placed it on the priority review track, with a May 1 target…
- WuXi Biologics and Fresenius strike major deal for up to 37 biosimilars over the next decadeWuXi Biologics and German drugmaker Fresenius have agreed to collaborate on the development and manufacturing of up to 37 biosimilar medicines over the next ten years. The agreement is described a…